Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Metabolomic Analysis of Patients with Chronic Myeloid Leukemia and Cardiovascular Adverse Events after Treatment with Tyrosine Kinase Inhibitors

Background: Cardiovascular adverse events (CV-AEs) are considered critical complications in chronic myeloid leukemia (CML) patients treated with second- and third-generation tyrosine kinase inhibitors (TKIs). The aim of our study was to assess the correlation between metabolic profiles and CV-AEs in...

Full description

Bibliographic Details
Main Authors: Giovanni Caocci, Martino Deidda, Antonio Noto, Marianna Greco, Maria Pina Simula, Olga Mulas, Daniele Cocco, Claudia Fattuoni, Giuseppe Mercuro, Giorgio La Nasa, Christian Cadeddu Dessalvi
Format: Article
Language:English
Published: MDPI AG 2020-04-01
Series:Journal of Clinical Medicine
Subjects:
Chronic myeloid leukemia
cardiovascular adverse events
tyrosine kinase inhibitors
GC-MS metabolomics
Online Access:https://www.mdpi.com/2077-0383/9/4/1180

Internet

https://www.mdpi.com/2077-0383/9/4/1180

Similar Items